- IBDEI3AJ ; ; 04-FEB-2020
- ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
- Q:'DIFQR(358.3) F I=1:2 S X=$T(Q+I) Q:X="" S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E S @X=Y
- Q Q
- ;;^UTILITY(U,$J,358.3,52519,2)
- ;;=^5002633
- ;;^UTILITY(U,$J,358.3,52520,0)
- ;;=E11.3211^^194^2540^22
- ;;^UTILITY(U,$J,358.3,52520,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,52520,1,3,0)
- ;;=3^DM Type 2 w/ Mild Nonp Rtnop w/ Macular Edema,Rt Eye
- ;;^UTILITY(U,$J,358.3,52520,1,4,0)
- ;;=4^E11.3211
- ;;^UTILITY(U,$J,358.3,52520,2)
- ;;=^5138331
- ;;^UTILITY(U,$J,358.3,52521,0)
- ;;=E11.3212^^194^2540^23
- ;;^UTILITY(U,$J,358.3,52521,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,52521,1,3,0)
- ;;=3^DM Type 2 w/ Mild Nonp Rtnop w/ Macular Edema,Lt Eye
- ;;^UTILITY(U,$J,358.3,52521,1,4,0)
- ;;=4^E11.3212
- ;;^UTILITY(U,$J,358.3,52521,2)
- ;;=^5138332
- ;;^UTILITY(U,$J,358.3,52522,0)
- ;;=E11.3213^^194^2540^24
- ;;^UTILITY(U,$J,358.3,52522,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,52522,1,3,0)
- ;;=3^DM Type 2 w/ Mild Nonp Rtnop w/ Macular Edema,Bilat
- ;;^UTILITY(U,$J,358.3,52522,1,4,0)
- ;;=4^E11.3213
- ;;^UTILITY(U,$J,358.3,52522,2)
- ;;=^5138333
- ;;^UTILITY(U,$J,358.3,52523,0)
- ;;=E11.40^^194^2540^10
- ;;^UTILITY(U,$J,358.3,52523,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,52523,1,3,0)
- ;;=3^DM Type 2 w/ Diab Neuropathy,Unspec
- ;;^UTILITY(U,$J,358.3,52523,1,4,0)
- ;;=4^E11.40
- ;;^UTILITY(U,$J,358.3,52523,2)
- ;;=^5002644
- ;;^UTILITY(U,$J,358.3,52524,0)
- ;;=E11.51^^194^2540^12
- ;;^UTILITY(U,$J,358.3,52524,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,52524,1,3,0)
- ;;=3^DM Type 2 w/ Diab Periph Angiopathy w/o Gangrene
- ;;^UTILITY(U,$J,358.3,52524,1,4,0)
- ;;=4^E11.51
- ;;^UTILITY(U,$J,358.3,52524,2)
- ;;=^5002650
- ;;^UTILITY(U,$J,358.3,52525,0)
- ;;=E11.52^^194^2540^11
- ;;^UTILITY(U,$J,358.3,52525,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,52525,1,3,0)
- ;;=3^DM Type 2 w/ Diab Periph Angiopathy w/ Gangrene
- ;;^UTILITY(U,$J,358.3,52525,1,4,0)
- ;;=4^E11.52
- ;;^UTILITY(U,$J,358.3,52525,2)
- ;;=^5002651
- ;;^UTILITY(U,$J,358.3,52526,0)
- ;;=E11.620^^194^2540^5
- ;;^UTILITY(U,$J,358.3,52526,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,52526,1,3,0)
- ;;=3^DM Type 2 w/ Diab Dermatitis
- ;;^UTILITY(U,$J,358.3,52526,1,4,0)
- ;;=4^E11.620
- ;;^UTILITY(U,$J,358.3,52526,2)
- ;;=^5002655
- ;;^UTILITY(U,$J,358.3,52527,0)
- ;;=E11.36^^194^2540^4
- ;;^UTILITY(U,$J,358.3,52527,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,52527,1,3,0)
- ;;=3^DM Type 2 w/ Diab Cataract
- ;;^UTILITY(U,$J,358.3,52527,1,4,0)
- ;;=4^E11.36
- ;;^UTILITY(U,$J,358.3,52527,2)
- ;;=^5002642
- ;;^UTILITY(U,$J,358.3,52528,0)
- ;;=I10.^^194^2541^1
- ;;^UTILITY(U,$J,358.3,52528,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,52528,1,3,0)
- ;;=3^Essential/Primary Hypertension
- ;;^UTILITY(U,$J,358.3,52528,1,4,0)
- ;;=4^I10.
- ;;^UTILITY(U,$J,358.3,52528,2)
- ;;=^5007062
- ;;^UTILITY(U,$J,358.3,52529,0)
- ;;=I11.0^^194^2541^12
- ;;^UTILITY(U,$J,358.3,52529,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,52529,1,3,0)
- ;;=3^Hypertensive Heart Disease w/ Heart Failure
- ;;^UTILITY(U,$J,358.3,52529,1,4,0)
- ;;=4^I11.0
- ;;^UTILITY(U,$J,358.3,52529,2)
- ;;=^5007063
- ;;^UTILITY(U,$J,358.3,52530,0)
- ;;=I11.9^^194^2541^13
- ;;^UTILITY(U,$J,358.3,52530,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,52530,1,3,0)
- ;;=3^Hypertensive Heart Disease w/o Heart Failure
- ;;^UTILITY(U,$J,358.3,52530,1,4,0)
- ;;=4^I11.9
- ;;^UTILITY(U,$J,358.3,52530,2)
- ;;=^5007064
- ;;^UTILITY(U,$J,358.3,52531,0)
- ;;=I12.0^^194^2541^5
- ;;^UTILITY(U,$J,358.3,52531,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,52531,1,3,0)
- ;;=3^Hypertensive CKD w/ Stage 5 CKD or ESRD
- --- Routine Detail --- with STRUCTURED ROUTINE LISTING ---[H[J[2J[HIBDEI3AJ 3761 printed Mar 13, 2025@21:49:52 Page 2
- IBDEI3AJ ; ; 04-FEB-2020
- +1 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
- +2 if 'DIFQR(358.3)
- QUIT
- FOR I=1:2
- SET X=$TEXT(Q+I)
- if X=""
- QUIT
- SET Y=$EXTRACT($TEXT(Q+I+1),4,999)
- SET X=$EXTRACT(X,4,999)
- if $ASCII(Y)=126
- SET I=I+1
- SET Y=$EXTRACT(Y,2,999)_$EXTRACT($TEXT(Q+I+1),5,999)
- if $ASCII(Y)=61
- SET Y=$EXTRACT(Y,2,999)
- XECUTE NO
- IF '$TEST
- SET @X=Y
- Q QUIT
- +1 ;;^UTILITY(U,$J,358.3,52519,2)
- +2 ;;=^5002633
- +3 ;;^UTILITY(U,$J,358.3,52520,0)
- +4 ;;=E11.3211^^194^2540^22
- +5 ;;^UTILITY(U,$J,358.3,52520,1,0)
- +6 ;;=^358.31IA^4^2
- +7 ;;^UTILITY(U,$J,358.3,52520,1,3,0)
- +8 ;;=3^DM Type 2 w/ Mild Nonp Rtnop w/ Macular Edema,Rt Eye
- +9 ;;^UTILITY(U,$J,358.3,52520,1,4,0)
- +10 ;;=4^E11.3211
- +11 ;;^UTILITY(U,$J,358.3,52520,2)
- +12 ;;=^5138331
- +13 ;;^UTILITY(U,$J,358.3,52521,0)
- +14 ;;=E11.3212^^194^2540^23
- +15 ;;^UTILITY(U,$J,358.3,52521,1,0)
- +16 ;;=^358.31IA^4^2
- +17 ;;^UTILITY(U,$J,358.3,52521,1,3,0)
- +18 ;;=3^DM Type 2 w/ Mild Nonp Rtnop w/ Macular Edema,Lt Eye
- +19 ;;^UTILITY(U,$J,358.3,52521,1,4,0)
- +20 ;;=4^E11.3212
- +21 ;;^UTILITY(U,$J,358.3,52521,2)
- +22 ;;=^5138332
- +23 ;;^UTILITY(U,$J,358.3,52522,0)
- +24 ;;=E11.3213^^194^2540^24
- +25 ;;^UTILITY(U,$J,358.3,52522,1,0)
- +26 ;;=^358.31IA^4^2
- +27 ;;^UTILITY(U,$J,358.3,52522,1,3,0)
- +28 ;;=3^DM Type 2 w/ Mild Nonp Rtnop w/ Macular Edema,Bilat
- +29 ;;^UTILITY(U,$J,358.3,52522,1,4,0)
- +30 ;;=4^E11.3213
- +31 ;;^UTILITY(U,$J,358.3,52522,2)
- +32 ;;=^5138333
- +33 ;;^UTILITY(U,$J,358.3,52523,0)
- +34 ;;=E11.40^^194^2540^10
- +35 ;;^UTILITY(U,$J,358.3,52523,1,0)
- +36 ;;=^358.31IA^4^2
- +37 ;;^UTILITY(U,$J,358.3,52523,1,3,0)
- +38 ;;=3^DM Type 2 w/ Diab Neuropathy,Unspec
- +39 ;;^UTILITY(U,$J,358.3,52523,1,4,0)
- +40 ;;=4^E11.40
- +41 ;;^UTILITY(U,$J,358.3,52523,2)
- +42 ;;=^5002644
- +43 ;;^UTILITY(U,$J,358.3,52524,0)
- +44 ;;=E11.51^^194^2540^12
- +45 ;;^UTILITY(U,$J,358.3,52524,1,0)
- +46 ;;=^358.31IA^4^2
- +47 ;;^UTILITY(U,$J,358.3,52524,1,3,0)
- +48 ;;=3^DM Type 2 w/ Diab Periph Angiopathy w/o Gangrene
- +49 ;;^UTILITY(U,$J,358.3,52524,1,4,0)
- +50 ;;=4^E11.51
- +51 ;;^UTILITY(U,$J,358.3,52524,2)
- +52 ;;=^5002650
- +53 ;;^UTILITY(U,$J,358.3,52525,0)
- +54 ;;=E11.52^^194^2540^11
- +55 ;;^UTILITY(U,$J,358.3,52525,1,0)
- +56 ;;=^358.31IA^4^2
- +57 ;;^UTILITY(U,$J,358.3,52525,1,3,0)
- +58 ;;=3^DM Type 2 w/ Diab Periph Angiopathy w/ Gangrene
- +59 ;;^UTILITY(U,$J,358.3,52525,1,4,0)
- +60 ;;=4^E11.52
- +61 ;;^UTILITY(U,$J,358.3,52525,2)
- +62 ;;=^5002651
- +63 ;;^UTILITY(U,$J,358.3,52526,0)
- +64 ;;=E11.620^^194^2540^5
- +65 ;;^UTILITY(U,$J,358.3,52526,1,0)
- +66 ;;=^358.31IA^4^2
- +67 ;;^UTILITY(U,$J,358.3,52526,1,3,0)
- +68 ;;=3^DM Type 2 w/ Diab Dermatitis
- +69 ;;^UTILITY(U,$J,358.3,52526,1,4,0)
- +70 ;;=4^E11.620
- +71 ;;^UTILITY(U,$J,358.3,52526,2)
- +72 ;;=^5002655
- +73 ;;^UTILITY(U,$J,358.3,52527,0)
- +74 ;;=E11.36^^194^2540^4
- +75 ;;^UTILITY(U,$J,358.3,52527,1,0)
- +76 ;;=^358.31IA^4^2
- +77 ;;^UTILITY(U,$J,358.3,52527,1,3,0)
- +78 ;;=3^DM Type 2 w/ Diab Cataract
- +79 ;;^UTILITY(U,$J,358.3,52527,1,4,0)
- +80 ;;=4^E11.36
- +81 ;;^UTILITY(U,$J,358.3,52527,2)
- +82 ;;=^5002642
- +83 ;;^UTILITY(U,$J,358.3,52528,0)
- +84 ;;=I10.^^194^2541^1
- +85 ;;^UTILITY(U,$J,358.3,52528,1,0)
- +86 ;;=^358.31IA^4^2
- +87 ;;^UTILITY(U,$J,358.3,52528,1,3,0)
- +88 ;;=3^Essential/Primary Hypertension
- +89 ;;^UTILITY(U,$J,358.3,52528,1,4,0)
- +90 ;;=4^I10.
- +91 ;;^UTILITY(U,$J,358.3,52528,2)
- +92 ;;=^5007062
- +93 ;;^UTILITY(U,$J,358.3,52529,0)
- +94 ;;=I11.0^^194^2541^12
- +95 ;;^UTILITY(U,$J,358.3,52529,1,0)
- +96 ;;=^358.31IA^4^2
- +97 ;;^UTILITY(U,$J,358.3,52529,1,3,0)
- +98 ;;=3^Hypertensive Heart Disease w/ Heart Failure
- +99 ;;^UTILITY(U,$J,358.3,52529,1,4,0)
- +100 ;;=4^I11.0
- +101 ;;^UTILITY(U,$J,358.3,52529,2)
- +102 ;;=^5007063
- +103 ;;^UTILITY(U,$J,358.3,52530,0)
- +104 ;;=I11.9^^194^2541^13
- +105 ;;^UTILITY(U,$J,358.3,52530,1,0)
- +106 ;;=^358.31IA^4^2
- +107 ;;^UTILITY(U,$J,358.3,52530,1,3,0)
- +108 ;;=3^Hypertensive Heart Disease w/o Heart Failure
- +109 ;;^UTILITY(U,$J,358.3,52530,1,4,0)
- +110 ;;=4^I11.9
- +111 ;;^UTILITY(U,$J,358.3,52530,2)
- +112 ;;=^5007064
- +113 ;;^UTILITY(U,$J,358.3,52531,0)
- +114 ;;=I12.0^^194^2541^5
- +115 ;;^UTILITY(U,$J,358.3,52531,1,0)
- +116 ;;=^358.31IA^4^2
- +117 ;;^UTILITY(U,$J,358.3,52531,1,3,0)
- +118 ;;=3^Hypertensive CKD w/ Stage 5 CKD or ESRD
